Patients reported that their daytime voiding frequency decreased from 9.5 times to 7.5 times per day, and nocturia (nighttime urination) resolved in 7 of 19 patients taking dulaglutide compared to only 1 of 16 patients on placebo
PubMed Central, Ravanbakhsh, Naseem, and Anil Kesavan
Check-in: If this is new or worsening, let your provider know promptly
However, its use may be restricted or prohibited in certain competitive sports organizations or athletic associations due to its potential performance-enhancing properties
In a documented case, a U.S
In addition, catabolic genes Atrogin-1 and MuRF-1 were also not changed by the supplementation (data not shown)